Special episode 5. John Dennis. Research breakthrough in Type 2 diabetes treatment.
One in Six BillionShow Notes
We talk to John Dennis, a data science researcher working in the University of Exeter. He used data from 1 million people with Type 2 diabetes to discover how the clinical characteristics of a patient alter the glucose lowering with different treatments. John’s 5 drug model, published in the Lancet in late February 2025, uses simple clinical information to identify, for the first time, the best glucose lowering treatment for a patient. The model selected best treatment lowers the glucos...
More from One in Six Billion
In the final episode of the One in Six Billion podcast Andrew and Maggie reflect with producer Steve Chapman on the fun they have had making 51 podcasts with 70 guests in the past 2 years. Send a text
Rohini Bajekal describes how she had years of receiving inappropriate lifestyle advice before Glucokinase MODY was diagnosed. Dr Shivani Misra’s research has shown that failure to diagnose monogenic diabetes is even common in South Asians than in the white European population. Send a text
Sarah Richardson talks about her new exciting research on insulin producing beta-cells that are single cells or small clusters rather than in islets. These extra-islet beta-cells make up most of the insulin producing capacity of the pancreas in young children and are particularly susceptible to immune attack in Type 1 diabetes. This important research explains why the loss of insulin producing cells in Type 1 diabetes is more severe in young children and informs future work on tre...
Hannah Robinson was the first adult in the UK to be given the new immunotherapy drug Teplizumab, which aims to slow down the development of type 1 diabetes. Hannah had multiple pancreatic autoantibodies and hence is on the path to developing Type 1 diabetes (Series 4 Episode 3). Her consultant, Nick Thomas, arranged 14 consecutive daily hospital visits for her to receive the drug through a drip. Send a text
Jerry Gore has always lived life on the edge; he had tackled some of the highest, and most inhospitable mountain climbs in the world before he was diagnosed with Type 1 diabetes aged 40. His Type 1 diabetes has not held him back and he has learnt how to live well with his Type 1 diabetes when climbing at extreme altitude and bitter cold. He helps people living with Type 1 diabetes throughout the world, especially in S E Asia as co-founder of Action4Diabetes (A4D). Rob Andrews is a...